Appointments signify POAI’s commitment to aligning board’s expertise with company’s strategic vision Board members to support development, commercialization of unique offering that improves outcomes for oncology patients, value to shareholders New appointments effective immediately Predictive Oncology (NASDAQ: POAI), a knowledge-driven … Continue reading →

Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis and working with distributor US Biological Corporation, has accomplished a major achievement. Recently, the company announced its first-ever commercial order of a novel ovarian cancer cell culture media for cancer cells collected … Continue reading →

TumorGenesis president Richard Gabriel selected to feature as keynote presenter at inaugural Drug Discovery & Preclinical Virtual Summit The summit features over 150 delegates from across bio-pharmaceutical industry coming together to market sector’s latest breakthroughs TumorGenesis, which specializes in creating … Continue reading →

Predictive Oncology (NASDAQ: POAI) has completed a strategic move to accelerate commercialization of its proprietary artificial intelligence “AI”-driven drug discovery and development. A recent article discussing Predictive Oncology’s recent acquisition of Quantitative Medicine (“QM”), a biomedical analytics and computational biology … Continue reading →

POAI’s TumorGenesis inks deal with top-rated medical university in New England Predictive’s proprietary media allows researchers around the world to isolate, culture ovarian cancer cell types, leading to new targets for treatment The TumorGenesis media retain more than 95% of … Continue reading →

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is on a well-funded path to move forward with its goals. A recent article discussing this quotes POAI CEO Dr. Carl … Continue reading →

POAI completes acquisition designed to accelerate commercialization of proprietary AI-driven drug discovery, development Strategic move allows for one-of-a-kind, end-to-end ‘discovery machine’ that can rapidly generate potential therapeutic candidates Company to offer new capability to pharmaceutical company customers in revenue-generating projects … Continue reading →

POAI improved liquidity position, streamlined capital structure with conversion of $2.1 million convertible note Business highlights include continued initial study to sequence ovarian tumors, validate “reach-back” Company closed transaction resulting in gross cash proceeds of approximately $2.2 million Predictive Oncology … Continue reading →